In 2017, the Centers for Medicare and Medicaid Services (CMS) made a milestone ruling, establishing benefit coverage for “therapeutic CGM”—a designation applying only to those continuous glucose monitoring (CGM) systems approved for use in making diabetes treatment decisions without a fingerstick (“non-adjunctive use”).* The Dexcom G5® CGM System is the first therapeutic CGM system covered as a Medicare benefit.
NEW! CGM coverage will include mobile device usage. Learn more.
*Fingersticks required for calibration of Dexcom G5, or if symptoms or expectations do not match readings, or when taking medications containing acetaminophen.